Cargando…

Separate and overlapping specificities in rheumatoid arthritis antibodies binding to citrulline- and homocitrulline-containing peptides related to type I and II collagen telopeptides

INTRODUCTION: Our objective was to find out if there are antibodies binding to homocitrulline-containing type I and II collagen carboxyterminal telopeptides in sera of patients with rheumatoid arthritis (RA), and if these antibodies cross-react with citrulline and homocitrulline in the same peptide...

Descripción completa

Detalles Bibliográficos
Autores principales: Turunen, Sanna, Hannonen, Pekka, Koivula, Marja-Kaisa, Risteli, Leila, Risteli, Juha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320812/
https://www.ncbi.nlm.nih.gov/pubmed/25573503
http://dx.doi.org/10.1186/s13075-014-0515-z
_version_ 1782356189966761984
author Turunen, Sanna
Hannonen, Pekka
Koivula, Marja-Kaisa
Risteli, Leila
Risteli, Juha
author_facet Turunen, Sanna
Hannonen, Pekka
Koivula, Marja-Kaisa
Risteli, Leila
Risteli, Juha
author_sort Turunen, Sanna
collection PubMed
description INTRODUCTION: Our objective was to find out if there are antibodies binding to homocitrulline-containing type I and II collagen carboxyterminal telopeptides in sera of patients with rheumatoid arthritis (RA), and if these antibodies cross-react with citrulline and homocitrulline in the same peptide sequence. METHODS: A total of 72 RA and 72 control sera were analyzed for binding using enzyme-linked immunosorbent assay to citrulline- or homocitrulline-containing type I and II collagen carboxyterminal telopeptides, as well as to cyclic citrullinated peptide (CCP) and to mutated citrullinated vimentin (MCV). Specificities of the antibodies were tested using inhibition-ELISA. RESULTS: Of the RA sera, 39 (54%) and 41 (57%) were positive for binding to CCP and MCV, respectively. Further, 34 (47%) and 30 (42%) of the patients had specific antibodies binding to and being inhibited by citrulline-containing type I collagen telopeptides and by citrulline-containing type II collagen carboxyterminal telopeptides, respectively. The corresponding figures regarding homocitrulline-containing type I and homocitrulline-containing type II collagen telopeptides were 16 (22%) and 14 (19%). Most of the patients, who were seropositive for citrullinated peptides, showed binding in multiple assays. A total of 10 (14%) RA patients were positive for all the tested peptide pairs, while 28 (39%) of them had antibodies that contained overlapping specifities between citrulline and homocitrulline in the same peptide sequence. CONCLUSIONS: Antibodies to both citrulline and homocitrulline containing type I and II collagen telopeptides can be found in sera of RA patients. These antibodies are not constant from one RA patient to another, but contain separate or overlapping specificities within the same peptide sequence varying between individuals. Our results suggest some relationship between citrulline and homocitrulline-recognizing antibodies, since homocitrulline antibodies exist mainly in individuals seropositive to anti-CCP and anti-MCV. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-014-0515-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4320812
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43208122015-02-09 Separate and overlapping specificities in rheumatoid arthritis antibodies binding to citrulline- and homocitrulline-containing peptides related to type I and II collagen telopeptides Turunen, Sanna Hannonen, Pekka Koivula, Marja-Kaisa Risteli, Leila Risteli, Juha Arthritis Res Ther Research Article INTRODUCTION: Our objective was to find out if there are antibodies binding to homocitrulline-containing type I and II collagen carboxyterminal telopeptides in sera of patients with rheumatoid arthritis (RA), and if these antibodies cross-react with citrulline and homocitrulline in the same peptide sequence. METHODS: A total of 72 RA and 72 control sera were analyzed for binding using enzyme-linked immunosorbent assay to citrulline- or homocitrulline-containing type I and II collagen carboxyterminal telopeptides, as well as to cyclic citrullinated peptide (CCP) and to mutated citrullinated vimentin (MCV). Specificities of the antibodies were tested using inhibition-ELISA. RESULTS: Of the RA sera, 39 (54%) and 41 (57%) were positive for binding to CCP and MCV, respectively. Further, 34 (47%) and 30 (42%) of the patients had specific antibodies binding to and being inhibited by citrulline-containing type I collagen telopeptides and by citrulline-containing type II collagen carboxyterminal telopeptides, respectively. The corresponding figures regarding homocitrulline-containing type I and homocitrulline-containing type II collagen telopeptides were 16 (22%) and 14 (19%). Most of the patients, who were seropositive for citrullinated peptides, showed binding in multiple assays. A total of 10 (14%) RA patients were positive for all the tested peptide pairs, while 28 (39%) of them had antibodies that contained overlapping specifities between citrulline and homocitrulline in the same peptide sequence. CONCLUSIONS: Antibodies to both citrulline and homocitrulline containing type I and II collagen telopeptides can be found in sera of RA patients. These antibodies are not constant from one RA patient to another, but contain separate or overlapping specificities within the same peptide sequence varying between individuals. Our results suggest some relationship between citrulline and homocitrulline-recognizing antibodies, since homocitrulline antibodies exist mainly in individuals seropositive to anti-CCP and anti-MCV. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-014-0515-z) contains supplementary material, which is available to authorized users. BioMed Central 2015-01-09 2015 /pmc/articles/PMC4320812/ /pubmed/25573503 http://dx.doi.org/10.1186/s13075-014-0515-z Text en © Turunen et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Turunen, Sanna
Hannonen, Pekka
Koivula, Marja-Kaisa
Risteli, Leila
Risteli, Juha
Separate and overlapping specificities in rheumatoid arthritis antibodies binding to citrulline- and homocitrulline-containing peptides related to type I and II collagen telopeptides
title Separate and overlapping specificities in rheumatoid arthritis antibodies binding to citrulline- and homocitrulline-containing peptides related to type I and II collagen telopeptides
title_full Separate and overlapping specificities in rheumatoid arthritis antibodies binding to citrulline- and homocitrulline-containing peptides related to type I and II collagen telopeptides
title_fullStr Separate and overlapping specificities in rheumatoid arthritis antibodies binding to citrulline- and homocitrulline-containing peptides related to type I and II collagen telopeptides
title_full_unstemmed Separate and overlapping specificities in rheumatoid arthritis antibodies binding to citrulline- and homocitrulline-containing peptides related to type I and II collagen telopeptides
title_short Separate and overlapping specificities in rheumatoid arthritis antibodies binding to citrulline- and homocitrulline-containing peptides related to type I and II collagen telopeptides
title_sort separate and overlapping specificities in rheumatoid arthritis antibodies binding to citrulline- and homocitrulline-containing peptides related to type i and ii collagen telopeptides
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320812/
https://www.ncbi.nlm.nih.gov/pubmed/25573503
http://dx.doi.org/10.1186/s13075-014-0515-z
work_keys_str_mv AT turunensanna separateandoverlappingspecificitiesinrheumatoidarthritisantibodiesbindingtocitrullineandhomocitrullinecontainingpeptidesrelatedtotypeiandiicollagentelopeptides
AT hannonenpekka separateandoverlappingspecificitiesinrheumatoidarthritisantibodiesbindingtocitrullineandhomocitrullinecontainingpeptidesrelatedtotypeiandiicollagentelopeptides
AT koivulamarjakaisa separateandoverlappingspecificitiesinrheumatoidarthritisantibodiesbindingtocitrullineandhomocitrullinecontainingpeptidesrelatedtotypeiandiicollagentelopeptides
AT ristelileila separateandoverlappingspecificitiesinrheumatoidarthritisantibodiesbindingtocitrullineandhomocitrullinecontainingpeptidesrelatedtotypeiandiicollagentelopeptides
AT ristelijuha separateandoverlappingspecificitiesinrheumatoidarthritisantibodiesbindingtocitrullineandhomocitrullinecontainingpeptidesrelatedtotypeiandiicollagentelopeptides